Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rozpoznanie zaawansowanego raka, który nie da się operować lub rozsiał się na inne organy
- •Widoczne guzy na badaniach obrazowych
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Przewidywana długość życia co najmniej 12 tygodni
- •Prawidłowe wyniki morfologii krwi i funkcji wątroby/nerek
- •Prawidłowe funkcje serca
- •Zdolność do podpisania zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.